

**VARNAVAS HADJIPANAYIS LTD (representing Novo Nordisk) 2021**

Date of publication: .....

	Full Name  <i>(Art. 1.01)</i>	HCPs: City of Principal Practice HCOs: city where registered  <i>(Art. 3)</i>	Country of Principal Practice  <i>(Schedule 1)</i>	Principal Practice Address  <i>(Art. 3)</i>	Unique country identifier <i>OPTIONAL</i>  <i>(Art. 3)</i>	Donations and Grants to HCOs <i>(Art. 3.01.1.a)</i>	Contribution to costs of Events <i>(Art. 3.01.1.b &amp; 3.01.2.a)</i>			Fee for service and consultancy <i>(Art. 3.01.1.c &amp; 3.01.2.c)</i>		TOTAL <i>OPTIONAL</i>
							Sponsorship agreements with HCOs / third parties appointed by HCOs to manage an Event	Registration Fees	Travel & Accommodation	Fees	Related expenses agreed in the fee for service or consultancy contract, including travel & accommodation relevant to the contract	
<b>HCPs</b>												
<i>INDIVIDUAL NAMED DISCLOSURE - one line per HCP (i.e. all transfers of value during a year for an individual HCP will be summed up: itemization should be available for the individual Recipient or public authorities' consultation only, as appropriate)</i>												
	Dr. Kalliopei Gerakiou	Limassol	Cyprus	5 Christou Economides, 3101	N/A	N/A	N/A	2.000 €	0 €	0 €	0 €	2.000 €
<i>OTHER, NOT INCLUDED ABOVE - where information cannot be disclosed on an individual basis for legal reasons</i>												
<b>Aggregate amount attributable to transfers of value to such Recipients - Art. 3.02</b>						N/A	N/A	Aggregate HCPs	Aggregate HCPs	Aggregate HCPs	Aggregate HCPs	Optional
<b>Number of Recipients in aggregate disclosure - Art. 3.02</b>						N/A	N/A	number	number	number	number	Optional
<b>% of the number of Recipients included in the aggregate disclosure in the total number of Recipients disclosed - Art. 3.02</b>						N/A	N/A	%	%	%	%	N/A
<b>HCOs</b>												
<i>INDIVIDUAL NAMED DISCLOSURE - one line per HCO (i.e. all transfers of value during a year for an individual HCO will be summed up: itemization should be available for the individual Recipient or public authorities' consultation only, as appropriate)</i>												
	Beyond Type 1 Cyprus - Σύνδεσμος Γονέων και Φίλων Παιδιών με Διαβήτη	Limassol	Cyprus	15 Nafpliou, 3025	N/A	0,00	500 €	0,00	0,00	0,00	0,00	500 €
	Ινστιτούτο Μελέτης Έρευνας και Εκπαίδευσης για το Σακχαρώδη Διαβήτη και τα Μεταβολικά Νοσήματα	Nicosia	Cyprus	48 Georgiou Griva Digeni	N/A	0,00	500 €	0,00	0,00	0,00	0,00	500 €
<i>OTHER, NOT INCLUDED ABOVE - where information cannot be disclosed on an individual basis for legal reasons</i>												
<b>Aggregate amount attributable to transfers of value to such Recipients - Art. 3.02</b>						Aggregate HCOs	Aggregate HCOs	Aggregate HCOs	Aggregate HCOs	Aggregate HCOs	Aggregate HCOs	Optional
<b>Number of Recipients in aggregate disclosure - Art. 3.02</b>						number	number	number	number	number	number	Optional
<b>% of the number of Recipients included in the aggregate disclosure in the total number of Recipients disclosed - Art. 3.02</b>						%	%	%	%	%	%	N/A
<b>R &amp; D</b>												
<b>AGGREGATE DISCLOSURE</b>												
Transfers of Value re Research & Development as defined - Article 3.04 and Schedule 1											TOTAL AMOUNT	OPTIONAL